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Background
Alzheimer’s Disease (AD) is the most common form of
dementia and is characterized by a progressive decline in cognition
and everyday function. For decades, AD research has centered
around the aggregation of amyloid and tau proteins. Evidence
indicates that the biochemical and cellular phases of the disease are
not entirely understood. There is a need for a better understanding
of the underlying disease processes to allow for early detection and
the ability to halt progression through more effective treatment
options. Proteomics research is capable of providing much of the
missing pieces when it comes to understanding the underlying
disease processes of AD.
Recently, Johnson et al. developed a mass spectrometry
pipeline utilizing tandem mass tag (TMT) technology which allowed
for quantification of proteins in brains from control, asymptomatic,
and symptomatic cases of AD.
The goal of this project was to expand upon the data published
from Johnson et al. by narrowing in on a comparison between
asymptomatic AD and AD protein abundances. The presented
findings arising from the computational analysis highlight interesting
biological processes that may shed more light into the mechanism
leading to disease progression in AD. Further study into these
mechanisms in AD can help increase our understanding and lead to
an eventual advancement in early intervention and better treatment
options for AD.
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Figure 1. Highlighted proteins are enriched in AD compared
to asymptomatic AD and are involved in the activation,
development, and differentiation of astrocytes.

Figure 2. Highlighted proteins are enriched in AD compared to
asymptomatic AD and are alpha subunits of the proteasome
playing a role in protein catabolism which in this case is
ubiquitin-independent.
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Illustration of the yellow beta-amyloid plaques and the blue
neurofibrillary tau tangles that disrupt neuron transmission and lead
to neurodegeneration.
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• Collection and Preparation of Samples
• TMT Pipeline and Protein Quantification
• Published Public Data
Investigation of Proteomics Data
• Using R Software and R Studio
• Filtered Data to Significant P-Values
• Filtered Significant P-Values to Significant P-Values for the
Difference of Asymptomatic AD – AD
• Filtered to Positive and Negative Differences in the P-Values of
Asymptomatic AD – AD
• Created a Volcano Plot to Display Protein Abundance Findings
• Ran a Gene Ontology (GO) Term Analysis of the Significant
Proteins
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• Enriched activation, development, and differentiation
processes of Astrocytes in AD
• Evidence points to astrocytes as an important biomarker
• Potential biomarker that can successfully diagnose,
differentiate, or predict the rate of decline between AD disease
stages
• Next Steps: Explore the relationship of astrocyte processes
comparing asymptomatic AD and cognitively healthy cases to
be able to understand astrocytes as biomarkers for the rate of
cognitive decline

Figure 3. Highlighted proteins are in significant abundance
when comparing asymptomatic AD and AD.
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Significant Changes in Protein Abundance

• Enriched ubiquitin-independent protein catabolic processes in
AD
• Process may be enriched for several reasons
• Over-compensation in degradation pathways to attempt
homeostasis as proteins aggregate in AD
• Lack of sufficient ubiquitin-dependent protein catabolism
• Normal tau degradation does not require ubiquitin
• Next Steps: Investigate proteasome interaction in AD to gain
insight which may prove helpful in developing treatment
options

• Proteomics research allows for a better understanding of the
underlying disease process of AD.
• Biological processes related to astrocyte activation, development,
and differentiation are enriched in AD compared to asymptomatic
AD.
• Ubiquitin-independent protein catabolic processes are also
enriched in AD compared to asymptomatic AD.
• Comparing the protein abundance between two stages of the
disease provides a way for early intervention methods to be
discovered and better treatment options developed.
• Future Step: Incorporate findings comparing between control and
asymptomatic data to better understand the underlying disease
processes.
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